Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP3A4 | P08684 | 1/20 | 0.50 |
| ▸ | CA1 | P00915 | 4/20 | 0.47 |
| ▸ | CA2 | P00918 | 4/20 | 0.47 |
| ▸ | CA12 | O43570 | 3/20 | 0.47 |
| ▸ | CA7 | P43166 | 3/20 | 0.47 |
| ▸ | CA9 | Q16790 | 3/20 | 0.47 |
| ▸ | CA14 | Q9ULX7 | 3/20 | 0.47 |
| ▸ | HSD17B10 | Q99714 | 3/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.44 |
| ▸ | TSHR | P16473 | 1/20 | 0.44 |
| ▸ | GABRA1 | P14867 | 1/20 | 0.44 |
| ▸ | GABRB2 | P47870 | 1/20 | 0.44 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.41 |
| ▸ | RHOA | P61586 | 1/20 | 0.39 |
| ▸ | MEN1 | O00255 | 2/20 | 0.39 |
| ▸ | GAA | P10253 | 2/20 | 0.39 |
| ▸ | MAPT | P10636 | 2/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.39 |
| ▸ | EP300 | Q09472 | 1/20 | 0.39 |
| ▸ | KAT2B | Q92831 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL301499 | 0.85 | CYP3A4 (0.63) | CYP3A4HSD17B10ALDH1A1TSHRGABRA1 | |
| SCHEMBL11303033 | 0.81 | CYP3A4 (0.67) | CYP3A4CA1CA2CA12CA7 | |
| SCHEMBL4606315 | 0.81 | CYP3A4 (0.46) | CYP3A4CA1CA2CA12CA7 | |
| SCHEMBL680146 | 0.80 | GABRA1 (0.52) | CA1CA2CA12CA7CA9 | |
| SCHEMBL18375540 | 0.80 | CA1 (0.57) | CYP3A4CA1CA2CA12CA7 | |
| SCHEMBL28664446 | 0.79 | HPGD (0.47) | CYP3A4CA1CA2CA12CA7 | |
| SCHEMBL22418858 | 0.79 | CYP3A4 (0.59) | CYP3A4CA1CA2HSD17B10ALDH1A1 | |
| 2-Allylphenol SCHEMBL8659599 | 0.79 | CYP3A4 (0.64) | CYP3A4CA1CA2HSD17B10ALDH1A1 | |
| SCHEMBL31429734 | 0.79 | GABRA1 (0.50) | CA1CA2CA12CA7CA9 | |
| SCHEMBL3803126 | 0.79 | KAT8 (0.56) | CA1CA2CA12CA7CA9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1944307-A2 | Synthetic Salicylihalamides, Apicularens and Derivatives Thereof | Board of Regents, The University of Texas System (US) | 2008-07-16 | — | — | EP | disclosed |
| EP-1944307-A2 | Synthetic Salicylihalamides, Apicularens and Derivatives Thereof | Board of Regents, The University of Texas System (US) | 2008-07-16 | — | — | EP | disclosed |
| US-6936723-B2 | Synthetic salicylihalamides, apicularens and derivatives thereof | BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM (US) | 2005-08-30 | — | — | US | disclosed |
| US-20040171672-A1 | Synthetic salicylihalamides, apicularens and derivatives thereof | BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM | 2004-09-02 | — | — | US | disclosed |
| US-6734209-B2 | MACROCYCLIC LACTONES HAVING ANTI-CANCER ACTIVITY AND VACUOLAR ATPASE INHIBITORY ACTIVITY | BOARD OF REGENTS THE UNIVERSITY OF TEXAS SYSTEM | 2004-05-11 | — | — | US | disclosed |
| US-20040063778-A1 | Synthetic salicylihalamides, apicularens and derivatives thereof | BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM | 2004-04-01 | — | — | US | disclosed |
| US-6617348-B1 | Treating or preventing osteoporosis | UT SOUTHWESTERN MEDICAL CENTER | 2003-09-09 | — | — | US | disclosed |
| EP-1307439-A2 | SYNTHETIC SALICYLIHALAMIDES, APICULARENS AND DERIVATIVES THEREOF | Board of Regents, The University of Texas System (US) | 2003-05-07 | — | — | EP | disclosed |
| WO-2002012223-A2 | SYNTHETIC SALICYLIHALAMIDES, APICULARENS AND DERIVATIVES THEREOF | BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM (US) | 2002-02-14 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040063778-A1 | Synthetic salicylihalamides, apicularens and derivatives thereof | ATP6V1H, ATP6V1G1, ATP6V1A | CYP3A4 185/4885CA1 3913/4885CA2 1576/4885 |
| US-20040171672-A1 | Synthetic salicylihalamides, apicularens and derivatives thereof | ATP6V1H, ATP6V1G1, ATP6V1A | CYP3A4 185/4885CA1 3913/4885CA2 1576/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.